Lupus

#EULAR2026 POS0172 #Lupus arthritis is the most common domain in RCTs but SLEDAI-MSK or BILAG-MSK isn’t satisfactory. Look out for the role out of LAMDA once externally validated using independent trial datasets. 4 candidates: SJC28, ESR, VAS Phy MSK, & VAS Pa Pain @RheumNow https://t.co/QJ51ETLSSN

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
EULAR flags

Day 3 EULAR Report

Jack Cush, MD

Day 3 was an interesting mix of posters, oral presentations, and review sessions on many practical subjects like osteoarthritis, large vessel vasculitis, systemic sclerosis, and pregnancy. Here are a few of my recommended abstracts from Friday at EULAR 2026.

Read Article
CAR T on purple background

5 years since Patient ID001: Progress on CAR-T Therapy in RMD

Md Yuzaiful Md Yusof, MRCP(UK), PhD

Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?

Read Article
A biomarker for CV disease in RA? Anti-CXCR3 antibodies asso w/ atherosclerosis Confirmed in a validation cohort Adding Ab profile to the mSCORE increases AUC from 0.6 to 0.9 Sens from 30 to 69% How does it compare with other ways of detecting atherosclerosis? #POS0899 https://t.co/O7bsLrVyzo

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
Can we have an effective, comprehensive score for #SLE #arthritis? #SLEDAI has a problem SJC>2 scores dames as ex #SJC=12 Meet #LAMBDA An attempt to improve a true positive #MSK OUTCOME in #lupus Needs validation esp in pts over time #EULAR2026 @RheumNow #POS1072 @eular_org https://t.co/fr0xuVqFnM

Links:

Janet Pope @Janetbirdope( View Tweet )
#EULAR2026 POS0306 Can we predict #lupus nephritis pts who would achieve CR at 12 mths? Monocentric study used M.Learning: developed & internally validated 5 Clinical Score (LUPRED) with AUC 0.75 training set, 0.78 validation. Simple to use but needs external validation @RheumNow https://t.co/1VRE1yBCac

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
lupus SLE

How to treat SLE in 2026 and beyond!

Janet Pope, MD, MPH, FRCPC

There are so many SLE trials, and over the last year, many new ideas have been suggested.

Read Article
#EULAR2026 POS0713 Is there a hope for BTK-inhibition in #SLE despite several previous failures? A Phase IIb RCT in China: primary endpoint (SRI-4) was met in Orelabrutinib vs PBO in dose-dependent manner. No new safety signal. Phase 3 RCT is underway @RheumNow https://t.co/4cJ8ezppTS

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#proof of #concept in #Sjogren’s #dis #lanalumab Treatment reduced in #SjD ✅reduced B cells in #salivary #glands —nearly complete depletion in serum ✅reduced B cell activation ✅improved #inflammation of #parotid & #submandibular glands @RheumNow #EULAR2026 #OP0163 #POS0284

Janet Pope @Janetbirdope( View Tweet )

EULAR flags

Updates in SLE and APS

2026 EULAR Press Release

Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) often overlap. While there have been some therapeutic advances, significant needs remain around diagnosis and monitoring, with a gap around definitions and biomarkers for refractory disease or specific subsets. EULAR – The

Read Article
Interim results from ASTER, a study on real world effectiveness of ANI in SLE: Pts receiving ANI had improvements in total SLEDAI-2K scores after 1 yr ffup period MCT, MSK & hema had the highest decrease in SLEDAI-2K scores from pre-tx to 1yr ffup OP342 @RheumNow #EULAR2026 https://t.co/DArOwQtxM6

Links:

sheila @RHEUMarampa( View Tweet )

#OP0336 Exploratory analyses from REGENCY👑 OBI +standard tx induced ⬆️ histological remission & markedly greater kidney tissue B-cell depletion vs PBO in lupus nephritis. Many patients without clinical CRR still achieved histologic remission. #EULAR2026 @RheumNow #EULARBest https://t.co/DoOlRO9QsC

Links:

Mrinalini Dey @DrMiniDey( View Tweet )
#OP0340 Long-term DARALUP data suggest CD38-targeting with daratumumab may be promising in refractory SLE, with rapid serologic and clinical improvements sustained to 84 weeks in many patients. Flares occurred in 6/10 patients but responded to belimumab. #EULAR2026 @RheumNow

Mrinalini Dey @DrMiniDey( View Tweet )

Post marketing safety signals of anifrolumab from US FDA adverse event reporting system - herpes zoster significantly associated. Others include infusion reactions and intermittent hypersensitivity @RheumNow ##EULAR2026 #POS1067

Bella Mehta @bella_mehta( View Tweet )

#EULAR2026 POS0683 Additional analysis of ALLEGORY RCT: in addition to meeting primary endpoint (SRI-4) and 5 key secondary endpoints, Obinutuzumab led to greater DORIS remission and LLDAS vs PBO in nonrenal #SLE. Under FDA review for license extension to non-renal @RheumNow https://t.co/HhZNX3w8v5

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#EULAR2026 OP0341 Phase I Obe-Cel Autologous CD19 CAR-T (advantage: 4-1BB-ζ, fast off-rate binding domain to reduce immunotoxicity) showed efficacy and acceptable safety with either 50M or 100M dose in N=13 patients with refractory #SLE. Need longterm data & comparators @RheumNow https://t.co/qxidRi0jit

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
OMRF study: Anti-Ro neg Sjögren’s patients share similar molecular profiling as anti-Ro positive pts: innate immune signaling, immune cell activation, inflammation, autophagy, apoptosis, and metabolic dysregulation pathways #EULAR2026 @RheumNow https://t.co/zJm6EbpyIB

Links:

TheDaoIndex @KDAO2011( View Tweet )
#EULAR2026 OP0340 WK84 data of single arm Phase 2 Daratumumab (CD38 plasma depleter) weekly for 8 doses with background IS in N=10 #SLE: rapid reduction of antidsDNA & efficacy. 6/10 relapsed from WK20; 5/10 had low IgG and needed IVIG. Promising but Not so durable @RheumNow https://t.co/UrTywqkQ4F

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#EULAR2026 OP0338 More evidence for treatment-to-target in #SLE. Longitudinal renal function analysis of Asia Pacific cohort: achieving LLDAS at least 50% of the time (LLDAS50) is assoc. with reduced eGFR decline independent of age, baseline eGFR, & renal involvement @RheumNow https://t.co/KduU1qtkhF

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

#EULAR2026 OP0336 Exploratory study of REGENCY RCT showed Obinutuzumab induced tissue depletion & histologic remission vs PBO. Interestingly, 53% OBI CRR non-responders had histologic remission. Better #lupus nephritis markers needed beyond proteinuria @RheumNow #EULARBest https://t.co/d8jPo9scvw

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#EULAR2026 OP0335 Open label extension study of Phase II Ianalumab RCT in #SLE: some patients treated with IAN for up to 1 year, had persistent benefits (median 44 wks post-IAN) following Bcell recovery. Important info to judiciously treat while balancing infection risk @RheumNow https://t.co/DEkGMYwy3H

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Dr. Laura Andreoli shares this slide showing the impact of rheumatic disease in reproductive health as described by Dr. MOstensen. These interplay of factors affect patients and should be taken into consideration when managing fertility & pregnancy. @RheumNow #EULAR2026 https://t.co/fB9kuD4kXo

Links:

sheila @RHEUMarampa( View Tweet )
#OP0337 In 48-week WILLOW🌳 LTE, oral TLR7/8 inhibitor enpatoran showed sustained improvements in cutaneous lupus activity with high CLASI-50/70 response rates and consistent safety profile across doses. Encouraging long-term data for CLE/SLE skin disease. #EULAR2026 @RheumNow https://t.co/6y0HjaTMqh

Links:

Mrinalini Dey @DrMiniDey( View Tweet )
#EULAR2026 OP0337 In double blind LTE WILLOW study, cutaneous efficacy (change in CLASI, CLASI 70/50) was maintained in Enpatoran, TLR 7/8-i by WK48. Those switched from PBO to ENP at WK24 also showed equal efficacy to ENP-ENP group. Promising treatment for #CLE #lupus @RheumNow https://t.co/0Plpy6c8At

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#EULAR2026 OP0220 How can we improve physical function of #SLE patients? Cross-sectional study of 2 US cohorts: poor physical function was associated with Fatigue, depression, learned helplessness and perceived stress. We should focus on improving fatigue & wellbeing @RheumNow https://t.co/vAFqYyuzgN

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

Therapeutic Updates

Expert insights on the 2024 ACR Guideline recommendations for lupus nephritis

Sponsored by Aurinia
Aurinia 2026 May RX Update
Two experts in lupus care offer a balanced perspective on applying the updated ACR Guideline recommendations and the clinical nuances of managing lupus nephritis.
Read Post

Recent Blogs

Advanced Practice Rheum

Systemic Lupus Erythematosus

Jack Cush, MD
APR SLE VIDEO COVER
Dr. Cush reviews systemic lupus erythematosus.
Read Article
Advanced Practice Rheum

Evaluation of Rheumatic Complaints

Jack Cush, MD
Eval of Rheum Complaints Cover Image
Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice.
Read Article
rheumthought

CNS Lupus (NPSLE)

Jack Cush, MD
Cush RhTh CNS
29 yr. old woman with SLE and transverse myelitis. Is this NPSLE; how to diagnose?
Read Article
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Podcasts

  • EULAR 2026 Daily Podcast Day 2c
  • EULAR 2026 Daily Podcast Day 1a
  • ACR 2025 Daily Podcasts Day4a
×